Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Zimmermann

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Bioorganic & Medicinal Chemistry|December 6, 2011
Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitorsPetra Ross-Macdonald, Heshani de Silva, Vishal Patel, et al.
Gut Pathogens|June 1, 2017
Comparison of clinical and immunological findings in gnotobiotic piglets infected with <i>Escherichia coli</i> O104:H4 outbreak strain and EHEC O157:H7Bettina Wöchtl, Florian Gunzer, Wilhelm Gerner, et al.
ACS Medicinal Chemistry Letters|March 18, 2021
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1Andrew P Degnan, Godwin K Kumi, Christopher W Allard, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2010
SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitorsKurt Zimmermann, Mark D Wittman, Mark G Saulnier, et al.
Cancer Research|May 4, 2005
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptorJoan M Carboni, Adrian V Lee, Darryl L Hadsell, et al.
Journal of Medicinal Chemistry|March 19, 2004
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor modelBalu N Balasubramanian, Denis R St Laurent, Mark G Saulnier, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2011
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.
Journal of Medicinal Chemistry|April 2, 2005
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11Mark G Saulnier, Balu N Balasubramanian, Byron H Long, et al.
Journal of Medicinal Chemistry|September 2, 2005
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activityMark Wittman, Joan Carboni, Ricardo Attar, et al.
Journal of Medicinal Chemistry|September 26, 2009
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical developmentMark D Wittman, Joan M Carboni, Zheng Yang, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry|December 6, 2011
Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitorsPetra Ross-Macdonald, Heshani de Silva, Vishal Patel, et al.
Gut Pathogens|June 1, 2017
Comparison of clinical and immunological findings in gnotobiotic piglets infected with <i>Escherichia coli</i> O104:H4 outbreak strain and EHEC O157:H7Bettina Wöchtl, Florian Gunzer, Wilhelm Gerner, et al.
ACS Medicinal Chemistry Letters|March 18, 2021
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1Andrew P Degnan, Godwin K Kumi, Christopher W Allard, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2010
SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitorsKurt Zimmermann, Mark D Wittman, Mark G Saulnier, et al.
Cancer Research|May 4, 2005
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptorJoan M Carboni, Adrian V Lee, Darryl L Hadsell, et al.
Journal of Medicinal Chemistry|March 19, 2004
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor modelBalu N Balasubramanian, Denis R St Laurent, Mark G Saulnier, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2011
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.
Journal of Medicinal Chemistry|April 2, 2005
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11Mark G Saulnier, Balu N Balasubramanian, Byron H Long, et al.
Journal of Medicinal Chemistry|September 2, 2005
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activityMark Wittman, Joan Carboni, Ricardo Attar, et al.
Journal of Medicinal Chemistry|September 26, 2009
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical developmentMark D Wittman, Joan M Carboni, Zheng Yang, et al.
Pageof 7